Rathbones Group PLC lifted its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 5.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 472,569 shares of the company's stock after purchasing an additional 24,915 shares during the quarter. Eli Lilly and Company accounts for approximately 2.0% of Rathbones Group PLC's holdings, making the stock its 13th biggest position. Rathbones Group PLC owned approximately 0.05% of Eli Lilly and Company worth $546,800,000 at the end of the most recent reporting period.
Other large investors have also recently modified their holdings of the company. TIAA CREF Individual & Institutional Services LLC increased its holdings in shares of Eli Lilly and Company by 4.9% during the 3rd quarter. TIAA CREF Individual & Institutional Services LLC now owns 41,526 shares of the company's stock valued at $48,049,000 after acquiring an additional 1,922 shares during the last quarter. FCA Corp TX raised its stake in shares of Eli Lilly and Company by 1.9% in the 3rd quarter. FCA Corp TX now owns 371 shares of the company's stock valued at $429,000 after acquiring an additional 7 shares in the last quarter. TIAA Trust National Association raised its stake in shares of Eli Lilly and Company by 74.1% in the 3rd quarter. TIAA Trust National Association now owns 879 shares of the company's stock valued at $1,017,000 after acquiring an additional 374 shares in the last quarter. Red Oak Financial Group LLC lifted its holdings in Eli Lilly and Company by 24.8% in the 3rd quarter. Red Oak Financial Group LLC now owns 694 shares of the company's stock worth $803,000 after purchasing an additional 138 shares during the last quarter. Finally, Mayflower Financial Advisors LLC lifted its holdings in Eli Lilly and Company by 2.5% in the 3rd quarter. Mayflower Financial Advisors LLC now owns 4,004 shares of the company's stock worth $4,633,000 after purchasing an additional 98 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.
Insider Activity at Eli Lilly and Company
In other news, EVP Anat Hakim sold 5,000 shares of the company's stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the completion of the transaction, the executive vice president directly owned 4,137 shares in the company, valued at $5,802,225.24. The trade was a 54.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.14% of the stock is currently owned by company insiders.
Trending Headlines about Eli Lilly and Company
These are some of the LLY headlines that stood out recently:
- Positive Sentiment: Health Canada approved Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes, potentially broadening the drug’s use and commercial opportunity. Article: Health Canada approves Lilly’s Mounjaro
- Neutral Sentiment: Recent updates cover studies of brenipatide, LY3839056, tirzepatide, and the cost of Alzheimer’s care. The reports describe study activity or updates, but the supplied information does not identify new efficacy results, so their near-term effect on valuation is unclear. Article: Lilly tests brenipatide in a depression study
- Negative Sentiment: Healthcare ETFs reportedly sold Lilly shares, including $17.4 million from IYH and $42.3 million from XLV. These sales may add some market pressure, though they appear to be fund-position changes rather than a company-specific development. Article: IYH sells Eli Lilly shares
Analysts Set New Price Targets
A number of brokerages have issued reports on LLY. HSBC upped their target price on Eli Lilly and Company from $850.00 to $940.00 and gave the stock a "reduce" rating in a research report on Thursday, September 10th. UBS Group lifted their price target on shares of Eli Lilly and Company from $1,425.00 to $1,625.00 and gave the company a "buy" rating in a research report on Friday, October 30th. Wells Fargo & Company boosted their price objective on shares of Eli Lilly and Company from $1,330.00 to $1,500.00 and gave the stock an "overweight" rating in a research note on Friday, October 30th. Weiss Ratings upgraded shares of Eli Lilly and Company from a "buy (b)" rating to a "buy (b+)" rating in a research note on Friday, November 13th. Finally, Argus upped their price objective on shares of Eli Lilly and Company from $1,300.00 to $1,550.00 and gave the stock a "buy" rating in a report on Friday, October 30th. One analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $1,422.00.
Check Out Our Latest Stock Report on LLY
Eli Lilly and Company Trading Down 0.3%
Eli Lilly and Company stock opened at $1,346.40 on Friday. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.00 and a current ratio of 1.39. The business's 50-day simple moving average is $1,268.06 and its 200-day simple moving average is $1,119.25. The firm has a market capitalization of $1.27 trillion, a PE ratio of 43.70, a PEG ratio of 1.71 and a beta of 0.40. Eli Lilly and Company has a 52 week low of $850.51 and a 52 week high of $1,475.25.
Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Thursday, October 29th. The company reported $7.48 earnings per share for the quarter, topping the consensus estimate of $5.71 by $1.77. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The business had revenue of $24.40 billion during the quarter, compared to analysts' expectations of $22.58 billion. During the same quarter in the previous year, the firm earned $7.02 EPS. The firm's revenue was up 38.6% compared to the same quarter last year. Equities research analysts forecast that Eli Lilly and Company will post 35.72 earnings per share for the current year.
Eli Lilly and Company Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be given a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend is Friday, November 13th. Eli Lilly and Company's payout ratio is currently 22.46%.
About Eli Lilly and Company
(
Free Report)
Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company's medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.
See Also
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.